Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model

Purpose: Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) is clinically evaluated as novel anticancer drug. rhTRAIL-DR5, a rhTRAIL variant that specifically binds to DR5 receptor, has recently been developed. We investigated whether rhTRAIL-DR5 is more efficient th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2009-03, Vol.15 (6), p.2048-2057
Hauptverfasser:	Duiker, Evelien W, de Vries, Elisabeth G E, Mahalingam, Devalingam, Meersma, Gert Jan, Boersma-van Ek, Wytske, Hollema, Harry, Lub-de Hooge, Marjolijn N, van Dam, Go M, Cool, Robbert H, Quax, Wim J, Samali, Afshin, van der Zee, Ate G J, de Jong, Steven
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic agents Antineoplastic Agents - pharmacology antitumor Biological and medical sciences bioluminescence Caspase 3 - metabolism Cell Line, Tumor cisplatin Cisplatin - pharmacology Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Luminescent Measurements Medical sciences Mice ovarian Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Pharmacology. Drug treatments Receptors, TNF-Related Apoptosis-Inducing Ligand - metabolism Recombinant Proteins - pharmacology Tissue Distribution TNF-Related Apoptosis-Inducing Ligand - pharmacokinetics TNF-Related Apoptosis-Inducing Ligand - pharmacology TNF-Related Apoptosis-Inducing Ligand - therapeutic use TRAIL Tumors Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!